announcements

⚡ Flash Summary

Citi Pharma Limited (CPHL) held its Annual General Meeting on October 27, 2025, where shareholders approved several key resolutions. These included confirming the minutes of the previous Extra Ordinary General Meeting, adopting the audited financial statements for the year ended June 30, 2025, and re-appointing M/s. Aslam Malik & Co. as external auditors. A final cash dividend of Rs. 3.5 per share (35%) was also approved for the financial year ended June 30, 2025. Furthermore, seven directors were elected to serve a three-year term.

📌 Key Takeaways

• ✅ Minutes from the Extra Ordinary General Meeting (EOGM) held on June 26, 2025, were confirmed.
• ✅ Audited Financial Statements for the year ended June 30, 2025, were received and adopted.
• ✅ M/s. Aslam Malik & Co. re-appointed as external auditors for the year ending June 30, 2026.
• 💰 Final cash dividend of Rs. 3.5 per share (35%) approved for the year ended June 30, 2025.
• 🗳️ Seven directors elected for a three-year term commencing October 27, 2025.
• 🗓️ Resolutions passed at the Annual General Meeting on October 27, 2025.
• 📜 Compliance with Listing Regulation No. 5.6.9(b) of the Pakistan Stock Exchange.
• 🏢 Meeting held at 588 Block Q, Phase 2 Johar Town, Lahore.
• 💼 Election of directors conducted under Section 166(3) of the Companies Act, 2017.
• 🤝 Unanimous passing of resolutions by the shareholders.
• ✔ Approval of the Board of Management’s recommendation for dividend payment.

🎯 Investment Thesis

A HOLD recommendation is appropriate at this time. The approval of resolutions and the dividend payout are positive signs, but a thorough understanding of the company’s financial performance based on the audited financial statements is necessary before making a definitive investment decision. Further information on revenue growth, profitability margins, and debt levels is required. Price target: Need more info. Time horizon: Medium Term.